Skip to main content
An official website of the United States government
Email

About the Radiopharmaceutical Therapy (RPT) Interest Group

 Theranostics represents a transformative approach in personalized medicine, offering tailored cancer treatments by integrating diagnostics with targeted radiotherapy. Several radiopharmaceuticals have been FDA-approved, expanding treatment options for advanced and refractory cancers:

Advances in isotope production and new ligands are broadening the scope of theranostics. Promising agents targeting HER2-positive cancers, rare tumors (e.g., meningiomas) or tumor microenvironment are in development. Novel radioisotopes, including Auger electron- and alpha particle-emitters hold potential for enhanced efficacy with minimal side effects.


These developments have reinvigorated interest in Radiopharmaceutical Therapy (RPT) and prompted establishment of the RPT Interest Group (IG), which was organized to bring together stakeholders from multiple disciplines, including physicians, basic scientists and clinical trial organizations, to provide a forum for free discussion of ideas regarding the development and use of radionuclide therapies.

 

GOALS

  1. Networking and discussion of new advances in the RPT field.
  2. Generation of ideas and establishment of best practices for clinical trials evaluating RPT.

Teleconference Schedule

  • The RPT Interest Group meets virtually via the WebEx platform once a month – the first Wednesday of each month at 5 pm ET.
  • The group membership is approximately 200.

 Activities and Accomplishments

Exchange of significant information and resources. Planning workshops.

Past Meetings

If you would like a list of presentations for presenters, topics, slide decks, and recordings from past meetings, please contact the Interest Group Coordinator, see below for information.

Interested in becoming a member of the RPT Interest Group?

Please Contact the Interest Group Coordinator:
     Jacek Capala, PhD Radiation Research Program National Cancer Institute
     Division of Cancer Treatment & Diagnosis
     Tel: 240-276-5706
     Email: jacek.capala@nih.gov
 

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “About the Radiopharmaceutical Therapy (RPT) Interest Group was originally published by the National Cancer Institute.”

Email